Approach and Registry of Anaphylaxis in Portugal

Detalhes bibliográficos
Autor(a) principal: Mota, Inês
Data de Publicação: 2015
Outros Autores: Pereira, Ana Margarida, Pereira, Celso, Tomaz, Elza, Ferreira, Manuel Branco, Sabino, Filipa, Coelho, Anabela, Santos, Anabela, Martins, Henrique, Morais-Almeida, Mário
Tipo de documento: Artigo
Idioma: por
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/6802
Resumo: Anaphylaxis has a growing incidence, especially in children. It represents a medical emergency and its successful therapy depends on early and proper intervention. Intramuscular epinephrine, with dose adjustment according to weight and age, is the drug of choice for anaphylaxis treatment. After resolution of the acute reaction, the patient should be kept under clinical surveillance for 6 to 24 hours, due to possible biphasic reactions. Prescription of an epinephrine auto injectable device should be considered in all patients with diagnosed or suspected anaphylaxis; additionally these patients should always be referred to an Immunoallergy consultation, to perform adequate investigation and management in order to reduce future risk. All anaphylaxis episodes must be recorded in The Portuguese Catalogue of Allergies and other Adverse Reactions (Catálogo Português de Alergias e outras Reações Adversas, CPARA), which represents a fundamental tool to share clinical information within the Health System. The present manuscript intends to disclose the most recent Portuguese guidelines for the diagnosis and treatment of anaphylaxis, making its clinical approach more effective and homogeneous, and to promote the use of The Portuguese Catalogue of Allergies and other Adverse Reactions as an essential tool to register and share information on anaphylaxis in Portugal.
id RCAP_40808b162e5b665626a5247ce57d2222
oai_identifier_str oai:ojs.www.actamedicaportuguesa.com:article/6802
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Approach and Registry of Anaphylaxis in PortugalAbordagem e Registo da Anafilaxia em PortugalAnaphylaxisEpinephrinePortugalRegistries.AnafilaxiaEpinefrinaPortugalSistema de Registos.Anaphylaxis has a growing incidence, especially in children. It represents a medical emergency and its successful therapy depends on early and proper intervention. Intramuscular epinephrine, with dose adjustment according to weight and age, is the drug of choice for anaphylaxis treatment. After resolution of the acute reaction, the patient should be kept under clinical surveillance for 6 to 24 hours, due to possible biphasic reactions. Prescription of an epinephrine auto injectable device should be considered in all patients with diagnosed or suspected anaphylaxis; additionally these patients should always be referred to an Immunoallergy consultation, to perform adequate investigation and management in order to reduce future risk. All anaphylaxis episodes must be recorded in The Portuguese Catalogue of Allergies and other Adverse Reactions (Catálogo Português de Alergias e outras Reações Adversas, CPARA), which represents a fundamental tool to share clinical information within the Health System. The present manuscript intends to disclose the most recent Portuguese guidelines for the diagnosis and treatment of anaphylaxis, making its clinical approach more effective and homogeneous, and to promote the use of The Portuguese Catalogue of Allergies and other Adverse Reactions as an essential tool to register and share information on anaphylaxis in Portugal.A anafilaxia apresenta uma incidência crescente, particularmente em idade pediátrica. Constituindo uma emergência médica, o sucesso terapêutico depende de uma intervenção precoce e adequada. A adrenalina por via intramuscular constitui o fármaco de eleição para o seu tratamento, devendo a dose ser ajustada ao peso e à idade. Resolvida a reação aguda, o doente deve ser mantido sob vigilância médica por um período de 6 a 24 horas, pelo risco de ocorrência de reações bifásicas. Deverá ser considerada a prescrição de um dispositivo de autoadministração de adrenalina em todos os doentes com diagnóstico ou suspeita de anafilaxia; adicionalmente estes doentes têm indicação formal para estudo em consulta de imunoalergologia, de modo a permitir uma adequada intervenção diagnóstica e terapêutica que reduzirá o risco futuro. Todos os episódios de anafilaxia devem ser registados no Catálogo Português de Alergias e outras Reações Adversas (CPARA), constituindo este um instrumento fundamental de partilha de informação clínica dentro do Sistema de Saúde. Este manuscrito pretende divulgar as orientações para o diagnóstico e tratamento da anafilaxia, tornando a sua abordagem clínica mais eficiente e consertada a nível nacional, e promover a adesão ao Catálogo Português de Alergias e outras Reações Adversas como um instrumento essencial de registo e partilha de informação dos episódios de anafilaxia ocorridos em Portugal.Ordem dos Médicos2015-10-20info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfapplication/pdfapplication/pdfapplication/pdfapplication/mswordapplication/pdfapplication/pdfapplication/pdfapplication/pdfapplication/pdfapplication/pdfapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/6802oai:ojs.www.actamedicaportuguesa.com:article/6802Acta Médica Portuguesa; Vol. 28 No. 6 (2015): November-December; 786-796Acta Médica Portuguesa; Vol. 28 N.º 6 (2015): Novembro-Dezembro; 786-7961646-07580870-399Xreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/6802https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/6802/4481https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/6802/7771https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/6802/7772https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/6802/7903https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/6802/7904https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/6802/8016https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/6802/8017https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/6802/8018https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/6802/8019https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/6802/8020https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/6802/8021https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/6802/8022https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/6802/8023https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/6802/8024https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/6802/8025Mota, InêsPereira, Ana MargaridaPereira, CelsoTomaz, ElzaFerreira, Manuel BrancoSabino, FilipaCoelho, AnabelaSantos, AnabelaMartins, HenriqueMorais-Almeida, Márioinfo:eu-repo/semantics/openAccess2022-12-20T11:04:59Zoai:ojs.www.actamedicaportuguesa.com:article/6802Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T16:19:22.124438Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Approach and Registry of Anaphylaxis in Portugal
Abordagem e Registo da Anafilaxia em Portugal
title Approach and Registry of Anaphylaxis in Portugal
spellingShingle Approach and Registry of Anaphylaxis in Portugal
Mota, Inês
Anaphylaxis
Epinephrine
Portugal
Registries.
Anafilaxia
Epinefrina
Portugal
Sistema de Registos.
title_short Approach and Registry of Anaphylaxis in Portugal
title_full Approach and Registry of Anaphylaxis in Portugal
title_fullStr Approach and Registry of Anaphylaxis in Portugal
title_full_unstemmed Approach and Registry of Anaphylaxis in Portugal
title_sort Approach and Registry of Anaphylaxis in Portugal
author Mota, Inês
author_facet Mota, Inês
Pereira, Ana Margarida
Pereira, Celso
Tomaz, Elza
Ferreira, Manuel Branco
Sabino, Filipa
Coelho, Anabela
Santos, Anabela
Martins, Henrique
Morais-Almeida, Mário
author_role author
author2 Pereira, Ana Margarida
Pereira, Celso
Tomaz, Elza
Ferreira, Manuel Branco
Sabino, Filipa
Coelho, Anabela
Santos, Anabela
Martins, Henrique
Morais-Almeida, Mário
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Mota, Inês
Pereira, Ana Margarida
Pereira, Celso
Tomaz, Elza
Ferreira, Manuel Branco
Sabino, Filipa
Coelho, Anabela
Santos, Anabela
Martins, Henrique
Morais-Almeida, Mário
dc.subject.por.fl_str_mv Anaphylaxis
Epinephrine
Portugal
Registries.
Anafilaxia
Epinefrina
Portugal
Sistema de Registos.
topic Anaphylaxis
Epinephrine
Portugal
Registries.
Anafilaxia
Epinefrina
Portugal
Sistema de Registos.
description Anaphylaxis has a growing incidence, especially in children. It represents a medical emergency and its successful therapy depends on early and proper intervention. Intramuscular epinephrine, with dose adjustment according to weight and age, is the drug of choice for anaphylaxis treatment. After resolution of the acute reaction, the patient should be kept under clinical surveillance for 6 to 24 hours, due to possible biphasic reactions. Prescription of an epinephrine auto injectable device should be considered in all patients with diagnosed or suspected anaphylaxis; additionally these patients should always be referred to an Immunoallergy consultation, to perform adequate investigation and management in order to reduce future risk. All anaphylaxis episodes must be recorded in The Portuguese Catalogue of Allergies and other Adverse Reactions (Catálogo Português de Alergias e outras Reações Adversas, CPARA), which represents a fundamental tool to share clinical information within the Health System. The present manuscript intends to disclose the most recent Portuguese guidelines for the diagnosis and treatment of anaphylaxis, making its clinical approach more effective and homogeneous, and to promote the use of The Portuguese Catalogue of Allergies and other Adverse Reactions as an essential tool to register and share information on anaphylaxis in Portugal.
publishDate 2015
dc.date.none.fl_str_mv 2015-10-20
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/6802
oai:ojs.www.actamedicaportuguesa.com:article/6802
url https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/6802
identifier_str_mv oai:ojs.www.actamedicaportuguesa.com:article/6802
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/6802
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/6802/4481
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/6802/7771
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/6802/7772
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/6802/7903
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/6802/7904
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/6802/8016
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/6802/8017
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/6802/8018
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/6802/8019
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/6802/8020
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/6802/8021
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/6802/8022
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/6802/8023
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/6802/8024
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/6802/8025
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/pdf
application/msword
application/pdf
application/pdf
application/pdf
application/pdf
application/pdf
application/pdf
application/pdf
application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Ordem dos Médicos
publisher.none.fl_str_mv Ordem dos Médicos
dc.source.none.fl_str_mv Acta Médica Portuguesa; Vol. 28 No. 6 (2015): November-December; 786-796
Acta Médica Portuguesa; Vol. 28 N.º 6 (2015): Novembro-Dezembro; 786-796
1646-0758
0870-399X
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799130644806107136